Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 79-85

  Lauria, F ^a,c   Raspadori, D ^b   Ventura, M A ^b   Rondelli, D ^b   Zinzani, P L ^b   Gherlinzoni, F ^b   Miggiano, M C ^b   Fiacchini, M ^b   Rosti, G ^b   Rizzi, S ^b   Tura, S ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Istituto di Ematologia Ed Oncologia Medica L e A Seragnoli   (Italy)

Author keywords

ABMT; HG NHL; IL 2; NK

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 9544230699     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Gribben JG, Goldstone AH, Linch DC et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still responsive to conventional dose therapy. J Clin Oncol 1989; 7: 1621-1629.
2. Colombat P, Gorin NC, Lemonnier MP et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas. J Clin Oncol 1990; 8: 630-637.
3. Grimm EA, Mazumder A, Zhang HZ, Rosemberg SA. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
4. Lotzova E, Savary CA, Herbermann RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987; 138: 2718-2727.
5. Rosenberg SA, Mule JJ, Spiess PJ et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant IL-2. J Exp Med 1985; 161: 1169-1190.
6. West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl J Med 1987; 316: 898-905.
7. Fierro MT, Xin-Sheng L, Lusso P et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988; 2: 50-54.
8. Foa R, Fierro MT, Tosti S et al. Induction and persistance of complete remission in a resistant acute myeloid leukemia patients following treatment with recombinant interleukin 2. Leuk Lymphoma 1990; 1: 113-117.
9. Foa R, Meloni G, Tosti S et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol 1991; 77: 491-496.
10. Maraninchi D, Blaise D, Viens P et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182-2187.
11. Lauria F, Zinzani PL, Rondelli D et al. Continuous infusion of interleukin-2 in two relapsed high grade non-Hodgkin's lymphoma patients: effectiveness and tolerability. Eur J Cancer 1991: 27: 521-522.
12. Gottlieb DJ, Prentice HG, Heslop HE et al. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood 1989; 74: 2335-2342.
13. Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-1097.
14. Meloni G, Foa R, Tosti S et al. Autologous bone marrow transplantation followed by interleukin 2 in children with advanced leukemia: a pilot study. Leukemia 1992; 6: 780-785.
15. Soiffer RJ, Murray C, Gonin R, Ritz J. Effects of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 94: 964-971.
16. Benyunes MC, Massumoto C, York A et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-163.
17. Hamon MD, Prentice HG, Gottlieb DJ et al. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 1993; 11: 399-401.
18. Baumgarten E, Schmid H, Pohl U et al. Low-dose natural interleukin-2 and recombinant interferon-gamma following aulologous bone marrow grafts in pediatric patients with high-risk acute leukemia. Leukemia 1994; 8: 850-855.
19. Niederwieser D, Gastl G, Rumpold H et al. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol 1987; 65: 301-306.
20. Jacobs R, Stoll M, Stratmann G et al. CD16-CD56+ natural killer cells after bone marrow transplantation. Blood 1992; 79: 3239-3244.
21. Tura S, Mazza P, Gherlinzoni F et al. High dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. Scan J Haematol 1986; 37: 347-352.
22. Atzpodien J, Korfer A, Evers P et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 1990; 2: 18-26.
23. Stein RC, Malkovska V, Morgan S et al. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin 2. Br J Cancer 1991; 63: 275-282.
24. Lissoni P, Barni S, Ardizzoia A et al. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 1992; 28: 92-99.
25. Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16- natural killer cells in vivo. J Exp Med 1990; 171: 1527-1532.
26. Caligiuri MA, Zmuidzinas A, Manley TJ et al. Functional consequences of interleukin 2 receptors expression on resting human lymphocytes. Identification of a novel natural killer subset with high affinity receptors. J Exp Med 1990; 171: 1509-1513.
27. Caligiuri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo following prolonged infusion of low-dose recombinant interleukin 2. J Clin Invest 1993; 91: 123-1328.
28. Reittie JE, Gottlieb DJ, Heslop HE et al. Endogenously generated activated killer cells circulate after autologous and allogeneic bone marrow transplantation. Blood 1989; 73: 1351-1358.
29. Favrot MC, Combaret V, Negrier S et al. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod 1990; 9: 167-177.
30. Bellone G, Fierro MT, Liao X-S et al. Lymphokine activated killer (LAK) cells inhibit the in vitro growth of myeloid and erithroid progenitor cells via the release of tumor necrosis factor-alpha. Leuk Lymphoma 1990; 1: 341-352.
31. Blay JY, Favrot MC, Negrier S et al. Correlation between clinical response to interleukin-2 therapy and sustained production of tumour necrosis factor. Cancer Res 1990; 50: 2371-2374.
32. McIntyre C, Chapman K, Reeder S et al. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants. Eur J Cancer 1992: 28: 58-63.
33. Heslop HE, Gottlieb DJ, Bianchi ACM et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 4: 1374-1380.